Amgen dismisses bone density concerns related to its weight-loss drug
Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone mineral density, a ...
Amgen stock falls as analysts mull over weight loss drug's bone density data
Analysts cited data from a phase one study showing the highest dose of Amgen’s MariTide was linked to roughly 4% loss of bone ...
Hosted on MSN1d
Amgen dismisses bone density concerns related to its new weight-loss drug
(Reuters) -Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, a ...
Amgen Defends Its Investigational Monthly Weight Loss Injection After Analyst Cites MariTide's Impact on Bone Density
On Tuesday, a Cantor analyst wrote that additional data from Amgen’s experimental weight loss injection, MariTide, suggests a ...
What’s Happening With Amgen Stock?
As an aside, in the tech space, see What’s Happening With Snap Stock? Although the recent Amgen update didn’t bode well with ...
Amgen Shares Drop 7% as Early Trial Data On Weight Loss Drug Raises Safety Concerns, Sparking...
Amgen shares dropped over 7% Tuesday after bone density data from an early-stage trial of its weight loss drug, MariTide, ...
Amgen slips as Cantor cites safety concerns linked to obesity candidate
Amgen (AMGN) stock falls as Cantor Fitzgerald raises safety concerns over bone mineral density loss linked to obesity ...
Amgen speaks out about bone density concerns with obesity drug
Amgen’s stock fell 7% after an analyst posted a note on MariTide’s influence on bone density which was noticed in a data ...
devdiscourse16h
Innovations and Challenges in Pharma: A Global Health Report
This health news summary explores various pharmaceutical developments including Novo Nordisk's phasing out of insulin pens, a ...
devdiscourse1d
Global Health Challenges: From Weight-Loss Wars to Vaccine Shortages
A roundup of top health news highlights Novo Nordisk's $16.5 billion deal scrutiny, Amgen's weight-loss drug controversy, ...
Amgen shares pare losses as drugmaker sees no bone safety concerns in obesity drug
CEO Bob Bradway said Amgen is "well advanced" in preparing to launch a Phase 3 testing round of MariTide in order to have ...
MarketWatch1d
Amgen Says No Link Between MariTide, Bone Density Loss
Amgen on Wednesday sought to allay concerns that its MariTide, investigational weight-loss shot could be linked to a loss of bone mineral density. Amgen shares fell more than 7% on Tuesday after a ...